Genetic Therapy Composition Manufacture TRIZ Cases
- Gene-Edited CAR-T Cells to Prevent Fratricide in T Cell Malignancies
Gene editing removes the target antigen and can block TCR signaling, helping CAR-T cells kill malignant T cells without self-destruction.
- Lipid-Coated Nanoparticles for Targeted Uptake and Transfection
Microfluidic lipid-coated nanoparticles improve targeted cellular uptake and transfection while reducing liver and spleen accumulation.
- Purified AAV Formulation for Stability and Aggregation Control
Buffer, cryoprotectant, and non-ionic surfactant combinations keep purified AAV particles stable and limit aggregation during storage and freeze-thaw.
- AAV Vector Stuffer Sequences for Residual DNA Purity
Inert stuffer polynucleotides fill AAV packaging capacity to limit residual DNA encapsidation and improve clinical-grade vector purity.
- Fratricide-Resistant CAR-T Cells for T Cell Malignancies
Target-antigen knockout makes CAR-T cells fratricide-resistant, preserving malignant T cell killing while reducing graft versus host risk.
- Acid-Degradable PEG Lipids for Stable mRNA LNP Endosome Escape
Acid-cleavable PEG lipids and self-assembling peptides stabilize mRNA LNPs in serum, then improve endosome escape and cell uptake.